— Know what they know.
Not Investment Advice

DXCM NASDAQ

DexCom, Inc.
1W: -8.4% 1M: -9.4% 3M: +4.5% YTD: +18.1% 1Y: +11.7% 3Y: -8.6% 5Y: -42.9%
$78.56
-0.01 (-0.01%)
 
Weekly Expected Move ±5.2%
$70 $74 $78 $82 $86
NASDAQ · Healthcare · Medical - Devices · Tech Score Sell · Power 48 · $29.6B mcap · 376M float · 1.22% daily turnover · Short 45% of daily vol
Credit Risk of going bust: lower than 80% of companies Debt: 4.5% of company value Bonds: $105.4M held by 25 funds → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 99.6%), DexCom, Inc. would be worth roughly what it owes.
Total debt $1.40B against a stock market value of $29.65B.
Distance to default 9.73 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $621.4M (short-term plus half of long-term), stock volatility 40.4%; Altman Z 7.02. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Smart Money Score
Bullish 75
Insider—
Congress1 trades
ETF Holdings—
Key Statistics
Market Cap$29.6B
52W Range54.11-92.59
Volume5,159,367
Avg Volume4,579,306
Beta1.48
Dividend—
Analyst Ratings
42 Buy 8 Hold 2 Sell
Consensus Buy
Company Info
CEOJacob Steven Leach
Employees11,050
SectorHealthcare
IndustryMedical - Devices
IPO Date2005-04-14
Websitedexcom.com
6340 Sequence Drive
San Diego, CA 92121
US
858 200 0200
About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Recent Insider Trades

NameTypeSharesPriceDate
Brown Michael Jon S-Sale 1,700 $85.48 2026-10-15
Stern Sadie S-Sale 2,565 $86.15 2026-09-28
AUGUSTINOS NICHOLAS S-Sale 6,539 $84.04 2026-09-15
Brown Michael Jon S-Sale 1,700 $84.04 2026-09-15
AUGUSTINOS NICHOLAS S-Sale 1,550 $84.02 2026-09-14

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms